As BeiGene works to change its corporate identity and grow the reach of its cancer offerings around the globe, the company ...
Robert F. Kennedy Jr.'s nomination as the Trump administration's Department of Health and Human Services (HHS) secretary has ...
On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...
Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for ...
Cardiometabolic disease biotech NeuroBo Pharmaceuticals is shaking up its corporate image with a complete rebrand. | ...
Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...
Neurology patient groups have chided the pharma industry for investing too little into treating disorders of the nervous ...
On the heels of the premiere of its first-ever Spanish-language Cologuard campaign, Exact Sciences is doubling down on its ...
After a labeling mix-up prompted a recall of a popular panic disorder drug this summer, Endo’s U.S. subsidiary is widening the scope of its product pull. | Endo USA is expanding its previous recall of ...
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...
The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback